An ongoing phase II, double-blind, parallel-group, placebo-controlled trial is evaluating the effects of apabetalone on PVR, 6MWD, NT-proBNP, and WHO functional class in 72 patients with PAH, including patients with simple CHD corrected for more than 1 year before inclusion [95]. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.